A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Gavilá J
- De La Haba J
- Bermejo B
- Rodríguez-Lescure Á
- Antón A
- Ciruelos E
- Brunet J
- Muñoz-Couselo E
- Santisteban M
- Rodríguez Sánchez CA
- Sánchez Rovira P
- García Sáenz JÁ
- Ruiz-Borrego M
- Guerrero-Zotano AL
- Huerta M
- Cotes-Sanchís A
- Lao Romera J
- Aguirre E
- Cortés J
- Llombart-Cussac A
Grupos
Abstract
To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L.
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 420-428
- PubMed:
- 31203575
- Factor de Impacto:
- 0,902 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical & Translational Oncology SPRINGER INT PUBL AG
Citas Recibidas en Web of Science: 8
Documentos
- No hay documentos
Filiaciones
Keywords
- Dual HER2 blockade, Human epidermal growth factor receptor 2 positive, Lapatinib, Metastatic breast cancer, Trastuzumab, Tyrosine kinase inhibitor
Portal de investigación